Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ci&ecir...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-09-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-retrospective-comparison-of-019-mg-fluocinolone-acetonide-a-peer-reviewed-article-OPTH |
| _version_ | 1818842538541318144 |
|---|---|
| author | Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B |
| author_facet | Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B |
| author_sort | Coelho J |
| collection | DOAJ |
| description | João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ciências Biomédicas Abel Salazar, Porto, PortugalCorrespondence: João CoelhoUnit of Ophthalmology, Centro Hospitalar Universitário do Porto, Largo Prof. Abel Salazar, Porto 4099-001, PortugalTel +351 91 765 6826Email joaomsmc@gmail.comPurpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.Methods: This was a non-interventional, retrospective, comparative study of 46 vitrectomized eyes in 33 patients with persistent or recurrent DME quantified best-corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) over up to 37 months.Results: Both FAc and DEX treatment led to statistically and clinically significant improvements in BCVA and CFT. FAc >10-letter improvement on the Early Treatment Diabetic Retinopathy Study [ETDRS] chart over months 3–24 and a sustained ∼200 μm CFT reduction over months 1–24; DEX: >5-letter improvement on the ETDRS chart at months 1 and 3 and >100 μm CFT reduction at month 1. FAc demonstrated sustained, stable and predictable effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a cohort of DME eyes that was refractory to DEX over 6 months.Conclusion: This real-world study demonstrates long-term effectiveness of FAc in vitrectomized DME eyes and sustained effectiveness in DME eyes that did not respond to DEX therapy.Keywords: diabetic macular edema, fluocinolone acetonide, dexamethasone implant, intravitreal implants, real-world, vitrectomy |
| first_indexed | 2024-12-19T04:43:34Z |
| format | Article |
| id | doaj.art-7d332ae5de2a45b99615deb965cb1585 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-19T04:43:34Z |
| publishDate | 2019-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-7d332ae5de2a45b99615deb965cb15852022-12-21T20:35:32ZengDove Medical PressClinical Ophthalmology1177-54832019-09-01Volume 131751175948461Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyesCoelho JMalheiro LMelo Beirão JMeireles APessoa BJoão Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ciências Biomédicas Abel Salazar, Porto, PortugalCorrespondence: João CoelhoUnit of Ophthalmology, Centro Hospitalar Universitário do Porto, Largo Prof. Abel Salazar, Porto 4099-001, PortugalTel +351 91 765 6826Email joaomsmc@gmail.comPurpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.Methods: This was a non-interventional, retrospective, comparative study of 46 vitrectomized eyes in 33 patients with persistent or recurrent DME quantified best-corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) over up to 37 months.Results: Both FAc and DEX treatment led to statistically and clinically significant improvements in BCVA and CFT. FAc >10-letter improvement on the Early Treatment Diabetic Retinopathy Study [ETDRS] chart over months 3–24 and a sustained ∼200 μm CFT reduction over months 1–24; DEX: >5-letter improvement on the ETDRS chart at months 1 and 3 and >100 μm CFT reduction at month 1. FAc demonstrated sustained, stable and predictable effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a cohort of DME eyes that was refractory to DEX over 6 months.Conclusion: This real-world study demonstrates long-term effectiveness of FAc in vitrectomized DME eyes and sustained effectiveness in DME eyes that did not respond to DEX therapy.Keywords: diabetic macular edema, fluocinolone acetonide, dexamethasone implant, intravitreal implants, real-world, vitrectomyhttps://www.dovepress.com/real-world-retrospective-comparison-of-019-mg-fluocinolone-acetonide-a-peer-reviewed-article-OPTHdiabetic macular edemafluocinolone acetonidedexamethasone implantintravitreal implantsreal-worldvitrectomy |
| spellingShingle | Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes Clinical Ophthalmology diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy |
| title | Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| title_full | Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| title_fullStr | Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| title_full_unstemmed | Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| title_short | Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| title_sort | real world retrospective comparison of 0 19 mg fluocinolone acetonide and 0 7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes |
| topic | diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy |
| url | https://www.dovepress.com/real-world-retrospective-comparison-of-019-mg-fluocinolone-acetonide-a-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT coelhoj realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT malheirol realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT melobeiraoj realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT meirelesa realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT pessoab realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes |